Levitra, which Bayer launched on the Korean market for erectile dysfunction drugs, withdrew completely on the 1st. It was withdrawn due to expiration of the validity period because Bayer Korea did not renew the license.
Only Kyongbo Vardenafil HCl of Kyongbo, a subsidiary of Chong Kun Dang, remains in the active ingredient containing Vardenafil HCl. According to the MFDS on the 1st, it was withdrawn due to the expiration of all four items of Bayer Korea's erectile dysfunction treatment Levitra.

In January, Bayer has informed distributors of the suspension of supply. It is explained that supply was inevitably stopped due to unstable supply and reduced demand due to the modernization of the plant